LayerBio, Inc news
LayerBio will present preclinical study results at the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii on Monday, April 30. These results demonstrate the therapeutic potential of its novel extended-release travoprost formulation using LayerBio`s proprietary PolyNet delivery technology.
LayerBio will present preclinical study results at the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii on Monday, April
Dr. Ken Mandell, Founder and CEO of LayerBio, presented an update on the development of its novel OcuRing-K ketorolac implant for treatment of postoperative pain and inflammation with cataract surgery.
OcuRing is a novel drug delivery platform for cataract surgery with potential to eliminate the need for postoperative topical eye drops. $3M DoD award will fund IND-enabling toxicology and manufacturing activities. LayerBio plans to develop OcuRing products for multiple cataract surgery-related indications.
OcuRing™ is a novel sustained-release technology designed to deliver therapies to cataract surgery patients, potentially eliminating the need for postoperati